The Microbiome Therapeutics Innovation Group (MTIG) announced the formation of their coalition which seeks to nurture innovation in microbiome therapeutics and microbiome-based products to address unmet medical needs and bring life-saving treatments to patients. The founding MTIG Board of Directors is comprised of Thomas J. DesRosier, Chairman of the MTIG Board and Executive Vice President, Chief Legal Officer and Secretary of Seres Therapeutics, Lee Jones, MTIG Secretary and Founder, President and Chief Executive Officer of Rebiotix Inc., and Bernat Olle, Co-founder and Chief Executive Officer of Vedanta Biosciences.
“The MTIG member companies are excited to work together to advance policy and regulatory solutions that support and sustain the development of safe, effective, microbiome therapeutics,” said Chairman DesRosier. “The emerging microbiome arena is a new frontier of medical innovation and holds promise for a variety of chronic diseases and some infections. We look forward to engaging with policymakers, government agencies, clinicians and patients on the role of the microbiome in human health, and the potential opportunities that novel microbiome products create for the field of medicine and patients in need.”
All pharmaceutical and biotechnology companies pursuing regulatory approvals for microbiome therapeutics and microbiome-based products are eligible for consideration of membership in MTIG. If you are interested in learning more about becoming a member, please contact us here.
About the Microbiome Therapeutics Innovation Group
The Microbiome Therapeutics Innovation Group (MTIG) is a coalition of companies leading the research and development of FDA-approved microbiome therapeutics and microbiome-based products to address unmet medical needs, improve clinical outcomes, and reduce health care costs. The human microbiome is one of the new frontiers of medical innovation that has the potential to benefit patients suffering from numerous diseases afflicting millions of patients and consuming billions of dollars of healthcare resources. MTIG is committed to working with stakeholders who share in our mission and seek tangible policy and regulatory solutions in the emerging microbiome arena. Through a collective voice, the MTIG membership works together to enhance the regulatory, investment, and commercial environment to accelerate microbiome therapeutic product development and enable the field to reach its potential to benefit patients.
Today, the MTIG is comprised of three companies: Rebiotix, Inc., Seres Therapeutics, and Vedanta Biosciences.
For more information, visit: www.microbiometig.org